Upfront nilotinib therapy among patients with chronic myeloid leukemia in chronic phase
Sign Up to like & getrecommendations! Published in 2017 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2017.1282697
Abstract: I have read with great interest the paper by Saydam et al. [1], reporting results of a company sponsored multicenter study from Turkey which evaluated the efficacy and safety of nilotinib 300 mg twice daily… read more here.
Keywords: chronic phase; myeloid leukemia; chronic myeloid; leukemia chronic ... See more keywords
Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial.
Sign Up to like & getrecommendations! Published in 2022 at "Future oncology"
DOI: 10.2217/fon-2022-0923
Abstract: Asciminib is the first BCR::ABL1 inhibitor that works by Specifically Targeting the ABL Myristoyl Pocket (STAMP). Asciminib has shown favorable efficacy and safety in patients with chronic myeloid leukemia in chronic phase without the T315I… read more here.
Keywords: myeloid leukemia; chronic myeloid; leukemia chronic; phase ... See more keywords